Gleevec (Imatinib) legal case

The Gleevec (Imatinib) legal case involves Novartis, the drug’s maker, defending against patent disputes. Generic companies challenged Novartis’s patent, arguing the patent was invalid, which could allow cheaper versions to be produced. Novartis argued the patent was valid, protecting their investment. The case overturning the patent in India led to increased access to affordable medication but also sparked debates over intellectual property rights versus public health. The case highlights conflicts between patent law, innovation, and access to life-saving drugs, emphasizing the delicate balance in global pharmaceutical regulation.